The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential hypertension - during baseline conditions and after activation of the sympathetic nervous system.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Regional Hospital Holstebro
• Treatments: Eprosartan; Hormones

Criteria

Inclusion Criteria:

• Age 18 - 65 years.

• Body mass index less or equal to 30 kg/m2.

• Women must use oral hormonal anticonceptive drugs, use intrauterine anticonceptive device, be sterilized / hysterectomized or be postmenopausal.

• Arterial hypertension, defined by 24 hour ambulatory blood pressure above 125 mmHg systolic or above 80 mmHg diastolic.

Exclusion Criteria:

• History of myocardial infarction.

• History of stroke.

• Heart failure.

• Endocrine organ disease.

• Lung disease.

• Clinically significant abnormal biochemical screening of the blood regarding:

B-hemoglobin, P-sodium, P-potassium, P-creatinine (under 200 µmol/L will be accepted), P-albumin, p-bilirubin, p-alaninaminotransferase, P-alkaline phosphatase, p-cholesterol and B-glucose.

• Clinically significant abnormal screening of the urine regarding: albumin and glucose (protein excretion below 0.5 g/L will be accepted).

• Renovascular hypertension.

• Malignant disease.

• Alcohol abuse.

• Usage of medical drugs besides antihypertensives or statins.

• Drug abuse.

• Pregnancy or breast feeding.

• Known intolerance or allergic to eprosartan or sodium nitroprusside.

• Blood donation within 1 month of the start of the study.